Novel Non-Hallucinogenic Compounds as 5‑HT2A Agonists for Treating Mental Health Disorders, Namely Depression, Anxiety, Stress Disorders, and Eating Disorders.
ACS Medicinal Chemistry Letters August 14, 2025 DOI: 10.1021/acsmedchemlett.5c00476 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Anxiety Depression |
| Key points | The document claims novel nonhallucinogenic 5-HT2A agonist compounds and their pharmaceutical compositions for treating depression, anxiety, stress disorders, and eating disorders, along with methods for their preparation. No biological or clinical results are presented. |
Abstract
Provided herein are novel nonhallucinogenic compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mental health disorders, namely depression, anxiety, stress disorders and eating disorders, and processes for preparing such compounds.
Citations in the library
Cites 4
- 5-HT2A receptors: Pharmacology and functional selectivity. Pharmacological Reviews April 23, 2025
- Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications. Brain Sciences January 25, 2025
- Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature. Brain Research 2025
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025